(Q37325019)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

title

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1 reference

1 reference

lymphoblastic leukemia

1 reference

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Mireia Morgades

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Josep-Maria Ribera

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

8

A K Fielding

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

9

S Giebel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

author name string

N Gökbuget

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

M Kelsh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

V Chia

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

A Advani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

R Bassan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

H Dombret

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

M Doubek

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

V Haddad

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

D Hoelzer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

C Holland

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

A Katz

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

T Maniar

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

G Martinelli

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

S O'Brien

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

J M Rowe

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

A Stein

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

M Topp

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

M Wadleigh

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

H Kantarjian

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

publication date

23 September 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

page(s)

e473

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

23 March 2020

copyright license

start time

1 September 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/bcj.2016.84

0 references

cites work

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

FDA Approval: Blinatumomab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Chimeric antigen receptor T cells for sustained remissions in leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Modern therapy of acute lymphoblastic leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Marginal structural models and causal inference in epidemiology

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056974

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

2 September 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.84

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.84

7 January 2021

The role of nonrandomized trials in the evaluation of oncology drugs

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.84

7 January 2021

The central role of the propensity score in observational studies for causal effects

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.84

7 January 2021

Estimating treatment effects using observational data

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2016.84

7 January 2021

Identifiers

DOI

10.1038/BCJ.2016.84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27662202%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1 reference